Marini JC, Blissett AR. New genes in bone development: what’s new in osteogenesis imperfecta. J Clin Endocrinol Metab 2013;98:3095–103.Google Scholar
Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos 2011;2011:540178.Google Scholar
Sillence DO. Osteogenesis imperfecta nosology and genetics. Ann N Y Acad Sci 1988;543:1–15.Google Scholar
Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111(5 Pt 1):1030–6.Google Scholar
Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996;129:432–9.Google Scholar
Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975;7:488–91.Google Scholar
Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 1993;45:261–4.Google Scholar
Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 1993;76:251–6.Google Scholar
Wright NM. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis. J Pediatr Endocrinol Metab 2000;13(Suppl 2):999–1002.Google Scholar
Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, et al. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res 2009;71:167–72.Google Scholar
Land C, Blum WF, Stabrey A, Schoenau E. Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency. Eur J Endocrinol 2005;152:727–33.Google Scholar
Hindmarsh PC, Dattani MT. Use of growth hormone in children. Nat Clin Pract Endocrinol Metab 2006;2:260–8.Google Scholar
Poidvin A, Touze E, Ecosse E, Landier F, Bejot Y, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology 2014;83:780–6.Google Scholar
Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005;20:758–63.Google Scholar
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80–101.Google Scholar
Veilleux LN, Lemay M, Pouliot-Laforte A, Cheung MS, Glorieux FH, et al. Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I. J Clin Endocrinol Metab 2013;99:E356–62.Google Scholar
Frost HM, Schonau E. The “muscle-bone unit” in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 2000;13:571–90.Google Scholar
Wu QQ, Chen Q. Mechanoregulation of chondrocyte proliferation, maturation, and hypertrophy: ion-channel dependent transduction of matrix deformation signals. Exp Cell Res 2000;256:383–91.Google Scholar
About the article
Published Online: 2016-04-18
Published in Print: 2016-07-01
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. The corresponding author confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Research funding: We thank “Deutsche Gesellschaft für Osteogenesis imperfecta (Glasknochen) Betroffene e.v.” including “Stiftung Baden-Württemberg” for financial research support.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.